Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 7Cisplatin 5pembrolizumab 4enfortumab vedotin 4Mitomycin 4Trastuzumab 3Pemetrexed 3Carboplatin 3dodecyl maltoside 2atezolizumab 2Sunitinib 2vinflunine 1valrubicin 1tucatinib 1palbociclib 1niraparib 1motexafin gadolinium 1cabozantinib 1avelumab 1apatorsen 1Water 1VMBP protocol 1Standard of Care 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Immunoglobulins, Intravenous 1Gels 1GSK-3326595 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urologic Neoplasms × VMBP protocol × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡